Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $2.06 is 50.46% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 2.169||$ 8.95|
|Low:||$ 2.05||$ 1.3691|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Our lead investigational product candidate is oncology therapeutic XBIO-101 (`sodium cridanimod') for the treatment of progestin - resistant endometrial cancer. We have exclusive rights to develop and commercialize XBIO-101 worldwide, except for specified countries in the Commonwealth of Independent States ("CIS"), including Russia. XBIO-101 has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the potential treatment of progesterone receptor negative ("PrR-") endometrial cancer in conjunction with progesterone therapy. We are currently conducting a Phase 2 trial for XBIO-101, with the first patient dosed in October 2017, and expect to generate preliminary data from this trial before the end of 2018. ... More ...
Nasdaq Official Price
Feb. 15, 2019
Feb. 15, 2019